JPMorgan says Pfizer’s (PFE) decision to discontinue development of danuglipron, an oral small molecule GLP-1, due to a liver toxicity issue in one patient, is “mostly a positive” for Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX). Structure is now in line to become the second small molecule oral to enter the market and Viking becomes an “even more attractive partnership candidate,” the analyst tells investors in a research note. JPMorgan believes Structure shares could be modestly up, to 5%, as a result of Pfizer’s update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking, Structure rally after Pfizer halts obesity drug development
- Affirm, Grab, Viking, Pfizer, Eli Lilly: Trending by Analysts
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics initiated with a Neutral at Goldman Sachs
- Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue